Oncolytics Biotech has shared encouraging results from its BRACELET-1 trial, revealing strong efficacy for its immunotherapy drug, pelareorep, in HR+/HER2- breast cancer patients. The trial demonstrated a significant improvement in survival rates, with patients on pelareorep + paclitaxel showing a 5.7-month progression-free survival benefit compared to chemotherapy alone. Based on these findings, the company is preparing for a Phase 2 trial in early 2025, potentially leading to an accelerated FDA approval for this treatment.
The company is also advancing its work in gastrointestinal cancers, particularly pancreatic cancer. Through collaborations with the Global Coalition for Adaptive Research (GCAR) and PanCAN, Oncolytics aims to explore pelareorep in combination with chemotherapy and immunotherapy in the GOBLET study. This includes plans to pursue regulatory approval for pelareorep in pancreatic cancer, building on its potential to improve outcomes in hard-to-treat cancers. Initial results for these therapies are anticipated in 2025.
Oncolytics’ broader oncology pipeline looks promising, with additional trials planned for pancreatic, anal, and other cancers. Pelareorep's demonstrated success across multiple indications highlights its versatility as an immunotherapy agent. With key studies slated for 2025, including safety and efficacy data from various cancer trials, Oncolytics is poised for significant advancements in cancer treatment.
Click here to read the original news story.